A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost biosimilar version of it is slated to hit the market this year.

Medicare selects Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower prices expected in 2028.

The 15 drugs selected for negotiation include Eli Lilly’s breast-cancer drug Verzenio.

Medicare wants to negotiate lower prices for Eli Lilly's GLP-1 drug Trulicity and AbbVie's Botox in its next round of drugmaker negotiations, federal health officials announced Tuesday. Why it matters ...

The Centers for Medicare and Medicaid Services said Tuesday it seeks to lower Medicare costs for 16 medications by negotiating with their manufacturers. Among them is Biktarvy, a drug taken after HIV ...

In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming price cuts under the Inflation Reduction Act (IRA), AbbVie is the late | The ...

NEW YORK (AP) — Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug ...

AbbVie Inc. is challenging the Trump administration’s decision to select its Botox drug for a government program that slashes ...

AbbVie sues HHS over Botox Medicare pricing, challenging CMS authority under the Inflation Reduction Act and drug price negotiation rules.

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...

While the 15 medications selected for the latest round of the federal government’s drug price negotiation program will face steep cuts in what Medicare will pay, the financial impact to pharmaceutical ...